Limbrick-Oldfield, E H
Mick, I
Cocks, R E
McGonigle, J
Sharman, S P
Goldstone, A P
Stokes, P R A
Waldman, A
Erritzoe, D
Bowden-Jones, H
Nutt, D http://orcid.org/0000-0002-1286-1401
Lingford-Hughes, A
Clark, L
Article History
Received: 25 February 2016
Revised: 12 September 2016
Accepted: 15 October 2016
First Online: 3 January 2017
Competing interests
: The National Problem Gambling Clinic (HBJ) receives some of its funding from the Responsible Gambling Trust. The Centre for Gambling Research at UBC (LC, EHL-O) is funded by the Province of British Columbia and the British Columbia Lottery Corporation. AW has received honoraria from Bayer, Novartis and GSK, and has been a consultant for Bayer. PRAS has received a speaking honorarium from Indivior and research funding from Corcept. LC has provided consultancy work for Cambridge Cognition, and has received a speaker honorarium from Svenska Spel. AL-H has received research funding/support from Lundbeck, GSK and honoraria for talks from Lundbeck. DN is the Chair and Director of the Independent Scientific Committee on Drugs (UK), has acted as an advisor to Lundbeck, MSD, Nalpharm, Orexigen, Shire, MSD and Actelion, has received speaker honorariums from the same organizations and also BMS/Otsuka, GSK, Lilly, Janssen, Servier, AZ, Pfizer, and is a shareholder in P1vital, Equasy Enterprises and Chaperon. SPS is currently part funded via a grant from the Responsible Gambling Trust (20%). The remaining authors declare no conflict of interest.